Last reviewed · How we verify
Fasudil hydrochloride combined with immunotherapy
Fasudil hydrochloride combined with immunotherapy is a Small molecule drug developed by baotai Liang. It is currently in Phase 2 development.
At a glance
| Generic name | Fasudil hydrochloride combined with immunotherapy |
|---|---|
| Sponsor | baotai Liang |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer (PHASE2)
- A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fasudil hydrochloride combined with immunotherapy CI brief — competitive landscape report
- Fasudil hydrochloride combined with immunotherapy updates RSS · CI watch RSS
- baotai Liang portfolio CI
Frequently asked questions about Fasudil hydrochloride combined with immunotherapy
What is Fasudil hydrochloride combined with immunotherapy?
Fasudil hydrochloride combined with immunotherapy is a Small molecule drug developed by baotai Liang.
Who makes Fasudil hydrochloride combined with immunotherapy?
Fasudil hydrochloride combined with immunotherapy is developed by baotai Liang (see full baotai Liang pipeline at /company/baotai-liang).
What development phase is Fasudil hydrochloride combined with immunotherapy in?
Fasudil hydrochloride combined with immunotherapy is in Phase 2.